Back to Discover

ZURA · Biotech · Nasdaq · As of 21 Nov 2026

Zura Bio Ltd stock: filings, catalysts and timeline

Sign in to follow

AIR Score

0100
43

Cautious · 43 / 100

AIR confidence

Support behind the full AIR read.

What is this? →

How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.

The Discovery Gap

LOWHIGHVERY HIGH

High

Gap confidence

How fully AIR could measure this Gap — separate from the AIR Score's confidence.

What is this? →

How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.

Five perspectives

  • FundamentalsWhat is this?Not scored — outside AIR's $300M–$20B fundamentals band

    How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.

    Source: SEC XBRL financial statements.

  • ValueWhat is this?Pre-revenue — no valuation basis

    How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.

    Source: SEC XBRL financial statements and end-of-day prices.

  • News flowWhat is this?Balanced

    What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.

    Source: SEC EDGAR 8-K filings and FDA approvals.

  • MomentumWhat is this?Weak

    The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.

    Source: End-of-day prices.

  • SafetyWhat is this?Balanced

    The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.

    Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.

Rating words, not raw numbers.

How AIR scores →

Discovery Gap: High (45/100) · Gap confidence 60/100

Discovery gap

Filings show more traction than the tape reflects.

Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.

What is this?

How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.

Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.

How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.

This month at a glance

AIR Score™ change: -6Slipped -6 on softer inputs.
Window31 Oct 2026 → 21 Nov 2026
Momentum-5Weighed on the score this month.

Evidence timeline

What changed — last 90 days

As of 11 Nov 2026
  1. The company reported Q3 2026 results with two Phase 2 tibulizumab trials fully enrolled exceeding targets with 247 participants in HS and 91 in SSc.

    Results · 8-K filed 27 Oct →

  2. The company filed its quarterly report for the period ending 30 September 2026.

    Quarterly/annual report · 10-Q filed 27 Oct →

What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.

  1. Expected
  2. Fri 19 Mar · expected 10-K

    Last year filed 19 Mar 2026.

  3. Fri 7 May · expected 10-Q

    Last year filed 7 May 2026.

  4. Filed
  5. Mon 9 Nov · 8-K

    8-K · Item 8.01 — Other events

    Recognition: Balanced 52 → Balanced 45Gap Very high · 51 → Very high · 45

    Market attention has faded.

    The gap narrowed as the filings read less positively.

    The price trend weakened.

  6. Tue 27 Oct · 8-K

    8-K · Item 2.02 — Results of operations

    Zura Bio reports Q3 2026 results with two Phase 2 tibulizumab trials fully enrolled exceeding targets (247 in HS, 91 in SSc), topline data on track for Q4 2026 and H1 2027. Third Phase 2 study (PMR) cleared by FDA to initiate by year-end. Cash position of $187.7M funds operations through end of 2028.

    Gap Very high · 50 → Very high · 57

    Progress is running ahead of attention.

    The price trend strengthened.

  7. Tue 27 Oct · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Very high · 50 → Very high · 57

    Progress is running ahead of attention.

    The price trend strengthened.

  8. Mon 17 Aug · 8-K

    Current report (8-K)

  9. Tue 11 Aug · 10-Q

    Quarterly report (10-Q), period ending 30 Jun 2026

  10. Tue 11 Aug · 8-K

    8-K · Item 2.02 — Results of operations

  11. Wed 1 Jul · 8-K

    Current report (8-K)

  12. Thu 18 Jun · 8-K

    8-K · Item 5.02 — Director or officer change

  13. Fri 22 May · 8-K

    8-K · Item 5.02 — Director or officer change

  14. Thu 7 May · 8-K

    8-K · Item 2.02 — Results of operations

  15. Thu 7 May · 10-Q

    Quarterly report (10-Q), period ending 31 Mar 2026

  16. Thu 23 Apr · 8-K

    8-K · Item 5.02 — Director or officer change

  17. Thu 19 Mar · 10-K

    Annual report (10-K), FY2025

  18. Thu 19 Mar · 8-K

    8-K · Item 2.02 — Results of operations

  19. Tue 10 Mar · 8-K

    Current report (8-K)

  20. Thu 5 Mar · 8-K

    Current report (8-K)

  21. Thu 26 Feb · 8-K

    8-K · Items 1.01, 2.02, 8.01 — Material agreement

  22. Mon 23 Feb · 8-K

    8-K · Item 5.02 — Director or officer change

  23. Wed 11 Feb · 8-K

    Current report (8-K)

  24. Mon 26 Jan · 8-K

    8-K · Item 5.02 — Director or officer change

  25. Mon 12 Jan · 8-K

    8-K · Item 8.01 — Other events

  26. Fri 2 Jan · 8-K

    8-K · Items 1.01, 1.02, 3.02, 8.01 — Material agreement

  27. Wed 17 Dec · 8-K

    8-K · Item 5.02 — Director or officer change

  28. Thu 13 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2025

  29. Thu 13 Nov · 8-K

    8-K · Item 2.02 — Results of operations

  30. Fri 10 Oct · 8-K

    8-K · Item 5.02 — Director or officer change

  31. Tue 30 Sep · 8-K

    8-K · Item 5.02 — Director or officer change

Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.